Vanguard Capital Management
ACRV icon

Vanguard Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Vanguard Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.26M Buy
1,104,024
+152,016
+16% +$289K ﹤0.01% 3336
2026
Q2 		$1.69M Buy
952,008
+229,973
+32% +$391K ﹤0.01% 3473
2026
Q1 		$1M Buy
+722,035
New +$1.26M ﹤0.01% 3550

Other funds holding ACRV

Sands Capital Ventures
Sands Capital Ventures Arlington, Virginia $695M AUM 31.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Empowered Funds
Empowered Funds Havertown, Pennsylvania $21.7B AUM 41.23% 1-Year Est. Return

Vanguard Capital Management's ACRV Position: Q3 2026 in Review

Vanguard Capital Management increased its Acrivon Therapeutics (ACRV) stake by 16% in Q3 2026, buying an estimated $289K and bringing the position to 1,104,024 shares worth $2.26M. The position accounts for ﹤0.01% of the portfolio, ranked #3336.

Vanguard Capital Management first reported a position in ACRV in Q1 2026 and has held it in 3 quarters since. 33 funds tracked by Wall St. Rank hold ACRV as of Q3 2026.

  • Vanguard Capital Management held 1,104,024 shares of Acrivon Therapeutics worth $2.26M as of Q3 2026.
  • Vanguard Capital Management bought 152,016 Acrivon Therapeutics shares in Q3 2026, an estimated $289K.
  • Acrivon Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3336 holding.
  • Vanguard Capital Management first reported a position in Acrivon Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 33 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.